Advertisement

Interferon: Current concepts of mechanisms of action

  • Paul P. Trotta
  • Robert J. Spiegel
Part of the Cancer Treatment and Research book series (CTAR, volume 36)

Abstract

Almost 30 years ago Isaacs and Lindenmann [1] discovered that the supernatant obtained from cells incubated with heat-inactivated influenza virus contained a substance capable of preventing the growth of active virus. This substance, named interferon (IFN), was later shown to be composed of a system of structurally related proteins that act directly on the target cells, not on the virus, and are produced by many types of animal cells in response to various external stimuli (e.g., viruses, certain types of double-stranded RNA, antigens, or mitogens). Three classes of IFNs have been described that differ in their amino acid sequences, as well as immunochemical and physicochemical properties: alpha (leukocyte), beta (fibroblast), and gamma (immune) IFN. Alpha and beta IFNs have also been designated as type I (acid-stable) and gamma IFN as type II (acid-labile). The alpha IFNs, which are produced by a variety of different cells including macrophages, null cells (non-B- and non-T-lymphocytes) and transformed B-cell lines, are a family of at least 14 species that share a 75% or greater amino acid sequence homology. Beta IFN, which shares ca30% amino acid sequence homology with alpha IFNs, is produced mainly by fibroblasts and epithelial cells, but may also be produced by human tumor cells derived from leukocytes (e.g., the Namalwa cell line). Gamma IFN is predominantly a product of T-cells and natural killer (NK) cells and shares little homology with type I IFNs.

Keywords

Human Alpha Interferon System Human Leukocyte Interferon Human Tumor Clonogenic Assay Friend Leukemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Isaacs A and Lindenmann J: Virus interference. The interferon. Proc R Soc B 147:258–267, 1957.Google Scholar
  2. 2.
    Paucker K, Cantell K, and Henle W: Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology 17:324–334, 1962.PubMedGoogle Scholar
  3. 3.
    Evinger M, Maeda S, and Pestka S: Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity. Arch Biochem Biophys 210:319–329, 1981.PubMedGoogle Scholar
  4. 4.
    Trotta PP: Summary of preclinical data. In: Interferon Alpha-2: Preclinical and Clinical Evaluation, DL Kisner and JF Smyth (eds). The Hague: Martinus Nijhoff Medical Division, p 13–27, 1985.Google Scholar
  5. 5.
    Lindahl P, Leary P, and Gresser I: Proc Natl Acad Sci 69: 721–726, 1972.PubMedGoogle Scholar
  6. 6.
    Stewart WE II: Varied biologic effects of interferon. In: Interferon-1979,I Gresser (ed). New York: Academic Press, vol 1, p 29–51, 1979.Google Scholar
  7. 7.
    Cantell K, Phyala L, and Strander H: Circulating human interferon after intramuscular injection into animals and man. J Gen Virol 25:453–458, 1974.PubMedGoogle Scholar
  8. 8.
    Streuli M, Nagata S, and Weissmann C: At least three human alpha interferons. Structure of alpha 2. Science 209:1343–1349, 1980.PubMedGoogle Scholar
  9. 9.
    Nagabhushan TL, Surprenant H, Le HV, Kosecki R, Levine A, Reichest P, Sharma B, Tsai H, Trotta P, Bausch J, Foster C, Gruber S, Hoogerheide J, and Mercorelli S: Characterization of genetically engineered alpha-2 interferon. In: Interferon: Research, Clinical Application and Regulatory Consideration, New York: Elsevier Science Publishers, p 79–88, 1984.Google Scholar
  10. 10.
    Stewart WE II: The Interferon System (2nd ed). New York: Springer-Verlag, 1981.Google Scholar
  11. 11.
    Pestka S (ed): Methods in Enzymology. Interferons (Part A), vol 78. New York: Academic Press, 1981.Google Scholar
  12. 12.
    Pestka S (ed): Methods in Enzmology. Interferons (Part B) vol 79. New York: Academic Press, 1981.Google Scholar
  13. 13.
    Baron S, Dianzani F, and Stanton GJ (eds): The Interferon System: A Review to 1982 — Part I, Galveston: Univ. of Texas Medical Branch Publishers, 1982.Google Scholar
  14. 14.
    Baron S, Dianzani F, and Stanton GJ (eds): The Interferon System: A Review to 1982 — Part II, Golveston: Univ of Texas Medical Branch Publishers, 1982.Google Scholar
  15. 15.
    Gresser I (ed): Interferon 1979, vol 1. New York: Academic Press, 1979.Google Scholar
  16. 16.
    Gresser I (ed): Interferon 1980, vol 2. New York: Academic Press, 1980.Google Scholar
  17. 17.
    Gresser I (ed): Interferon 1982, vol 3. New York: Academic Press, 1982.Google Scholar
  18. 18.
    Gresser I (ed): Interferon 1983, vol 4. New York: Academic Press, 1983.Google Scholar
  19. 19.
    Gresser I (ed): Interferon 1985, vol 5. New York: Academic Press, 1985.Google Scholar
  20. 20.
    Gresser I (ed): Interferon 1986, vol 6. New York: Academic Press, 1986.Google Scholar
  21. 21.
    Billiau A (ed): Interferon 1. General and Applied Aspects, vol 1. Amsterdam: Elsevier Science Publishers, 1984.Google Scholar
  22. 22.
    Vilcek J and DeMaeyer E (ed): Interferon 2. Interferons and the Immune System, vol 2. New York: Elsevier Science Publishers, 1984.Google Scholar
  23. 23.
    Friedman RM (ed): Interferon 3. Mechanisms of Production and Action, vol 3. New York: Elsevier Science Publishers, 1984.Google Scholar
  24. 24.
    Finter NB and Oldham RK (ed): Interferon 4. In vivo and clinical studies, vol 4. New York: Elsevier Science Publishers, 1985.Google Scholar
  25. 25.
    Welander CE, Morgan TM, Homesley HD, Trotta PP, and Spiegel RJ: Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 35:721–729, 1985.PubMedGoogle Scholar
  26. 26.
    Salmon SE, Durie BGM, Young L, Liu RM, Trown PW, and Stebbing N: Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217–225, 1983.PubMedGoogle Scholar
  27. 27.
    Friedman RM: Interferon binding: The first step in establishment of antiviral activity. Science 156:1760–1761, 1967.PubMedGoogle Scholar
  28. 28.
    Branca A and Baglioni C: Evidence that types I and II interferons have different receptors. Nature 294:768–771, 1981.PubMedGoogle Scholar
  29. 29.
    Aguet M and Blanchard B: High affinity binding of 125I-labelled mouse interferon to a specific cell surface receptor. Virology 115:249–261, 1981.PubMedGoogle Scholar
  30. 30.
    Zoon KC, Zur Nedden D, and Arnheiter H: Specific binding of human alpha interferon to a high affinity cell surface binding site on bovine kidney cells. J Biol Chem 257:4695–4697, 1982.PubMedGoogle Scholar
  31. 31.
    Joshi AR, Sarkar FH, and Gupta SL: Interferon receptors. Crosslinking of human leukocyte interferon alpha-2 to its receptor on human cells. J Biol Chem 257:13774–13887, 1982.Google Scholar
  32. 32.
    Littman SJ, Faltynek CR, and Baglioni C: Binding of human recombinant 125I-interferon gamma to receptors on human cells. J Biol Chem 260:1191–1195, 1985.PubMedGoogle Scholar
  33. 33.
    Faltynek CR, Branca A, McCandless S, and Baglioni C: Characterization of an interferon receptor on human lymphoblastoid cells. Proc Natl Acad Sci USA 80:3269–3273, 1983.PubMedGoogle Scholar
  34. 34.
    Hannigan GE, Gewert DR, and Williams BRG: Characterization and regulation of alpha-interferon receptor expression in interferon-sensitive and -resistant human lymphoblastoid cells. J Biol Chem 259:9456–9460, 1984.PubMedGoogle Scholar
  35. 35.
    Baglioni C, Branca AA, D’Alessandro SB, Hossenlopp D, and Chadha KC: Low interferon binding of two human cell lines which respond poorly to the antiviral and antiproliferative activity of interferon. Virology 122:202–206, 1982.PubMedGoogle Scholar
  36. 36.
    Affabris E, Belardelli F, Jemma C, Mechti N, Gresser I, and Rossi GB: 2–5 A synthetase activity does not increase in interferon-resistant Friend leukemia cell variants treated with alpha/beta interferon despite the presence of high-affinity interferon receptor sites. Virology 125:508–512, 1983.PubMedGoogle Scholar
  37. 37.
    Branca AA, Faltynek CR, D’Alessandro SB, and Baglioni C: Interaction of interferon with cellular receptors. Internalization and degradation of cell-bound interferon. J Biol Chem 257:13291–13296, 1982.PubMedGoogle Scholar
  38. 38.
    Sarkar FH and Gupta SL: Interferon receptor interaction: Internalization of interferon-alpha-2 and modulation of its receptor on human cells. Eur J Biochem 140:461–467, 1984.PubMedGoogle Scholar
  39. 39.
    Ankel H, Chany C, Galliot B, Chevalier MJ, and Robert M: Antiviral effect of interferon covalently bound to Sepharose. Proc Natl Acad Sci 70:2360–2363, 1973.PubMedGoogle Scholar
  40. 40.
    Branca AA and Baglioni C: Down-regulation of the interferon receptor. J Biol Chem 257:13197–13200, 1982.PubMedGoogle Scholar
  41. 41.
    Anderson P, Yip YK, and Vilcek J: Specific binding of 125I-human interferon-gamma to high affinity receptors on human fibroblasts. J Biol Chem 257:11301–11304, 1982.PubMedGoogle Scholar
  42. 42.
    Weil J, Epstein LB, and Epstein CJ: Synthesis of interferon-induced polypeptides in normal and chromosome 21-aneuploid human fibroblasts: Relationship to relative sensitivities in antiviral assays. J Interferon Res 1, 111–124, 1980.PubMedGoogle Scholar
  43. 43.
    Weil J, Epstein CJ, Epstein LB, Sedmak JJ, Sabram JL, and Grossberg SE: A unique set of polypeptides is induced by gamma-interferon, in addition to those induced in common with IFN-alpha and IFN-beta. Nature 301:437–439, 1983.PubMedGoogle Scholar
  44. 44.
    Zerial H, Hovanessian AG, Stefanos S, Huygen K, Werner GH, and Falcoff E: Synergistic activities of type I (alpha, beta) and type II (gamma) murine interferons. Antiviral Res 2:227–239, 1982.PubMedGoogle Scholar
  45. 45.
    Weigent DA, Langford MP, Fleischmann Jr WR, and Stanton GJ: Potentiation of lymphocyte natural killing by mixtures of alpha or beta interferon with recombinant gamma interferon. Infect Immun 40:35–38 (1983).PubMedGoogle Scholar
  46. 46.
    Fleischmann WR, Jr Kleyn KM, and Baron S: Potentiation of antitumor activity of virus-induced interferon by mouse immune interferon preparations. J Natl Cancer Inst 65:963–966, 1980.PubMedGoogle Scholar
  47. 47.
    Fleischmann WR Jr: Potentiation of the direct anticellular activity of mouse interferons: Mutual synergism and interferon concentration dependence. Cancer Res 42:869–875, 1982.PubMedGoogle Scholar
  48. 48.
    Braun W and Levy HB: Interferon preparations as modifiers of immune responses. Proc Soc Exp Biol Med 141:769–773, 1972.PubMedGoogle Scholar
  49. 49.
    Johnson HM and Baron S: Regulatory role of interferons in the immune response. IRCS J Med Sci 4:50–52, 1976.Google Scholar
  50. 50.
    Herberman RB, Ortaldo JR, and Bonnard GD: Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 277:221–223, 1979.PubMedGoogle Scholar
  51. 51.
    Herberman RB, Ortaldo JR, Rubinstein M, and Pestka S: Augmentation of natural and antibody-dependent cell mediated cytotoxicity by pure human leukocyte interferon. J Clin Immunol 1:149–153, 1981.PubMedGoogle Scholar
  52. 52.
    Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung HF, and Pestka S: Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol 67:160–167, 1982.PubMedGoogle Scholar
  53. 53.
    Platsoucas CD, Galinski M, Higgins J, Keen J, Feckert HJ, and Trotta PP: Regulation of natural killer cytotoxicity and of proliferative responses of human leukocytes by recombinant alpha interferons. Antiviral Research, abst 1, no 3, p 74, 1984.Google Scholar
  54. 54.
    Einhorn S, Ahre A, Blomgren H, Johansson B, Mellstedt H, and Strander H: NK Cells and Other Natural Effector Cells.New York: Academic Press, p 1259–1263, 1982.Google Scholar
  55. 55.
    Lotzova E, Savary CA, Gutterman JU, and Hersh EM: Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-alpha. Cancer Res 42:2480–2488, 1982.PubMedGoogle Scholar
  56. 56.
    Maluish AE, Ortaldo JR, Conlon JC, Sherwin SA, Leavitt R, Strong DM, Wiernik P, Oldham RK, and Herberman RB: Depression of natural killer cytotoxicity following in vivo administration of recombinant leukocyte interferon. J Immunol 131:503–507, 1983.PubMedGoogle Scholar
  57. 57.
    Trinchieri G and Santoli D: Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 147:1314–1333, 1978.PubMedGoogle Scholar
  58. 58.
    Schultz RM: Macrophage activation by interferons. In: Lymphokine Reports, vol 1, E Pick (ed). New York: Academic Press, p 63–97, 1980.Google Scholar
  59. 59.
    Meltzer M, Benjamin B, and Farrar JJ: Macrophage activation for tumor cytotoxicity; induction of macrophage tumoricidal activity by lymphokines from EL-4, a continuous cell line. J Immunol 129:2802–2807, 1982.PubMedGoogle Scholar
  60. 60.
    Le J, Prensky W, Yip YK, Chang Z, Hoffman J, Stevenson HC, Balazs I, Sadlik JR, and Vilcek J: Activation of human monocyte cytotoxicity by natural and recombinant immune interferon. J Immunol 131:2821–2826, 1983.PubMedGoogle Scholar
  61. 61.
    Hokland ME: Immunomodulatory effects of interferons on human mononuclear cells with special reference to the expression of cell surface antigens. Acta Pathologica, Microbio-logica et Immunologica Scandinavica 93:4–35, 1985.Google Scholar
  62. 62.
    Heron I and Berg K: The actions of interferon are potentiated at elevated temperatures. Nature 274:508–510, 1978.PubMedGoogle Scholar
  63. 63.
    Itoh K, Inoue M, Kataoka S, and Kumagai K: Differential effect of interferon on expression of IgG-and IgM-Fc receptors on human lymphocyte. J Immunol 124:2589–2595, 1980.PubMedGoogle Scholar
  64. 64.
    Wong GHW, Clark-Lewis I, McKim-Breschkin JL, and Schrader JW: Proc Natl Acad Sci (USA) 79:6989–6993, 1982.Google Scholar
  65. 65.
    Basham TY and Merigan TC: Recombinant interferon-gamma increases HLA-Dr synthesis and expression. J Immunol 130:1492–1494, 1983.PubMedGoogle Scholar
  66. 66.
    Gisler RH, Lindahl P, and Gresser I: Effects of interferons on antibody synthesis in vitro. J Immunol 113:438–444, 1974.PubMedGoogle Scholar
  67. 67.
    Vignaux F, Gresser I, and Friedman WH: Effect of virus-induced interferon on the antibody response of suckling and adult mice. Eur J Immunol 10:375–379, 1980.Google Scholar
  68. 68.
    Taylor JL, Sabran JL, and Grossberg SE: The cellular effects of interferon. In: Interferons and their Applications, PE Came, and WA Carter (eds). New York: Springer-Verlag, p 169–204, 1984.Google Scholar
  69. 69.
    Strander H and Einhorn S: Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer 19:468–473, 1977.PubMedGoogle Scholar
  70. 70.
    Adams A, Strander H, and Cantell K: Sensitivity of Epstein-Barr virus transformed human lymphoid cell lines to interferon. J Gen Virol 28:207–217, 1975.PubMedGoogle Scholar
  71. 71.
    Balkwill FR and Bokhon’ko AI: Differential effects of pure human alpha and gamma interferons on fibroblast cell growth and the cell cycle. Exp Cell Res 155:190–197, 1984.PubMedGoogle Scholar
  72. 72.
    Krueger LJ, Terry RW, Sussman AJ, Tate AC, and Axelrod DE: Interferon-induced growth modulation: Low-dose maintenance of the antiproliferative response. J Interferon Res 4:29–40, 1984.PubMedGoogle Scholar
  73. 73.
    Balkwill FR, Watling D, and Taylor-Papadimitriou J: Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast. Int J Cancer 22:258–265, 1978.PubMedGoogle Scholar
  74. 74.
    Balkwill F and Taylor-Papadimitriou J: Interferon affects both Gtand S + G2in cells stimulated from quiescence to growth. Nature 274:798–800, 1978.PubMedGoogle Scholar
  75. 75.
    Heston WDW, Fleischmann, J, Tackett RE, and Ratliff TL: Effects of alpha-difluoromethylornithine and recombinant interferon-alpha-2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice. Cancer Res 44:3220–3225, 1984.PubMedGoogle Scholar
  76. 76.
    Taylor-Papadimitriou J, Shearer M, Balkwill FR, and Fantes KH: Effects of HuIFN alpha-2 and HuIFN-alpha (Namalwa) on breast cancer cells grown in culture and as xenografts in the nude mouse. J Interferon Res 21:479–491, 1982.Google Scholar
  77. 77.
    Gresser I and Bourali-Maryu C: The antitumor effect of interferon in lymphocyte and macrophage depressed mice. Proc Soc Exp Biol Med 144:896–900, 1973.PubMedGoogle Scholar
  78. 78.
    Fisher PB, Miranda HF, Babiss LE, Pestka S, and Weinstein IB: Opposing effects of interferon produced in bacteria and of tumor promoters and myogenesis in human myoblast cultures. Proc Nat’l Acad Sci 80:2961–2965, 1983.Google Scholar
  79. 79.
    Lough J, Keay S, Sabran JL, and Grossberg SE: Inhibition of chicken myogenesis in vitro by partially purified interferon. Biochem Biophys Res Commun 109:92–99, 1982.PubMedGoogle Scholar
  80. 80.
    Dolei A, Colletta G, Capobianchi MR, Rossi GB, and Vecchio G: Interferon effects on Friend leukemia cells. I. Expression of virus and erythroid markers in untreated and dimethyl sulphoxide-treated cells. J Gen Virol 46:227–236, 1980.PubMedGoogle Scholar
  81. 81.
    Cioe L, Dolei A, Rossi GB, Belardelli F, Affabris E, Gambari E, and Fantoni A: Potential for differentiation, virus production, and tumorigenicity in murine erythroleuke-mic cells treated with interferon. In: In Vitro Aspects of Erythropoiesis New York (ed).: Springer-Verlag, p 159–171, 1978.Google Scholar
  82. 82.
    Cioe L, O’Brien TG, and Diamond L: Inhibition of adipose conversion of Balb/c 3T3 cells by interferon and 12–0-tetradecanoyl-phorbol-13-acetate. Cell Biol Int Rep 4:255–264, 1980.PubMedGoogle Scholar
  83. 83.
    Keay S and Grossberg SE: Interferon inhibits the conversion of 3T3-L1 mouse fibroblasts into adipocytes. Proc Natl Acad Sci 77:4099–4103, 1980.PubMedGoogle Scholar
  84. 84.
    Fisher PB, Mufson RA, and Weinstein IB: Interferon inhibits melanogenesis in B-16 mouse melanoma cells. Biochem Biophys Res Commun 100:823–830, 1981.PubMedGoogle Scholar
  85. 85.
    Takei M, Takeda K, and Konno K: The role of interferon-gamma in induction of differentation of human myeloid leukemia cell lines, ML-1 and HL-60. Biochem Biophys Res Commun 124:100–105, 1984.PubMedGoogle Scholar
  86. 86.
    Tomida M, Yamamoto Y, and Hozumi H: Stimulation by interferon of induction of differentiation of human promyelocytic leukemic cells. Biochem Biophys Res Commun 104:30–37, 1982.PubMedGoogle Scholar
  87. 87.
    Fisher PB, Prignoli DR, Hermo Jr H, Weinstein IB, and Pestka S: Effects of combined treatment with interferon and mezerein or melanogenesis and growth in human melanoma cells. J Interferon Res 5:11–22, 1985.PubMedGoogle Scholar
  88. 88.
    Greiner JW, Hand PH, Noguchi P, Fisher PB, Pestka S, and Schlom J: Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res 44:3208–3214, 1984.PubMedGoogle Scholar
  89. 89.
    Friedman, RM: Cell surface alterations induced by interferon. In: Methods in Enzymol-ogy, Interferons (Part B) vol 79, S Pestka (ed). New York: Academic Press, p 458–461, 1981.Google Scholar
  90. 90.
    Pestka S and Baron S: Definition and classification of the interferons. In: Methods in Enzymology. Interferons (Part A) vol 78, S Pestka (ed). New York: Academic Press, p 3–14, 1981.Google Scholar
  91. 91.
    Lengyel P: Biochemistry of interferons and their actions. In: Ann Rev Biochem, EE Snell, PD Boyer, A Meister, and CC Richardson (eds). 51:251–282, 1982.Google Scholar
  92. 92.
    Baglioni C: The molecular mediators of interferon action. In: Interferons and their Applications, PZ Came and WA Carter (eds). New York: Springer-Verlag, p 153–168, 1984.Google Scholar
  93. 93.
    Taylor-Papadimitriou J: Effects of interferons on cell growth and function. In: Interferon 1. General and Applied Aspects, A Billiau (ed). Amsterdam: Elsevier Press, p 139–166, 1984.Google Scholar
  94. 94.
    Farrell PJ, Sen GC, Dubrois MF, Ratner L, Slattery E, and Lengyel P: Interferon action: Two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci 75:5893–5897, 1978.PubMedGoogle Scholar
  95. 95.
    Kimchi A, Schulman I, Schmidt A, Chernajovsky Y, Fradin A, and Revel M: Kinetics of the induction of 3 translation-regulatory enzymes by interferon. Proc Natl Acad Sci 76:3208–3212, 1979.PubMedGoogle Scholar
  96. 96.
    Creasy AA, Eppstein DA, Marsh YV, Khan Z, and Merigan J: Growth-regulation of melanoma cells by interferon and (2’-5’)oligoadenylate synthetase. Mol Cell Biol 3:780–786, 1983.Google Scholar
  97. 97.
    Yarden A, Shure-Gottlieb H, Chebath J, Revel M, and Kimchi A: Autogenous production of interferon-beta switches on HLA genes during differentiation of histiocytic lymphoma U937 cells. EMBO J 3:969–973, 1984.PubMedGoogle Scholar
  98. 98.
    Silverman RH, Watling D, Balkwill FR, Trowsdale J, and Kerr IM: The ppp(A2’p)nA and protein kinase system in wild type and interferon-resistant Daudi cells. Eur J Biochem 126:333–341, 1982.PubMedGoogle Scholar
  99. 99.
    Fuse A and Kawata T: Inhibition of DNA synthesis and alteration of cyclic adenosine 3’,5’-monophosphate levels in RSa cells by human leukocyte interferon. J Natl Cancer Inst 60:1227–1232, 1978.PubMedGoogle Scholar
  100. 100.
    Sekar V, Atmar UJ, Joshi AR, Krim M, and Kuehn GD: Inhibition of ornithine decarboxylase in human fibroblast cells by type I and type II interferons. Biochem Biophys Res Commun 114:950–954, 1983.PubMedGoogle Scholar
  101. 101.
    Lee E and Sreevalsen T: Interferon as an inhibitor of polyamine enzymes. In: Advances in Polyamine Research, vol 3, CM Calarena, V Zappra, and U Bachrach (eds). New York: Raven Press, p 175–186, 1981.Google Scholar
  102. 102.
    Bourgeade MF and Chang C: Inhibition of interferon action by cytochalasin B, calchiane, and vinblastine. Proc Soc Exp Biol Med 153:501–504, 1976.PubMedGoogle Scholar
  103. 103.
    Pfeffer LM, Wang E, and Tamm I: Interferon effects on microfilament organization, cellular fibronectin distribution, and cell motility in human fibroblasts. J Cell Biol 85:9–17, 1980.PubMedGoogle Scholar
  104. 104.
    Jonak GJ and Knight Jr E: Selective reduction of c-myc mRNA in Daudi cells by interferon. Proc Natl Acad Sci 81:1747–1750, 1984.PubMedGoogle Scholar
  105. 105.
    Gresser I, Maury C, and Tovey M: Efficacy of combined interferon-cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur J Cancer 14:97–99, 1978.PubMedGoogle Scholar
  106. 106.
    Tozawa M, Kidowaki T, Tanaka R, Sawada R, Kusunoki T, Oku T, and Kishida T: Effects of interferon on C1300 mouse neuroblastoma. Cancer Treatment Rep 66:1575–1577, 1982.Google Scholar
  107. 107.
    Heremans H, Billiau A, and DeSomer P: Effect of interferon on the growth of tumours in experimental murine models. In: The Biology of the Interferon System, E De Maeyer and H Schellekens (eds). Amsterdam: Elsevier Press, p 425–430, 1983.Google Scholar
  108. 108.
    Chirigos MA and Pearson JW: Cure of murine leukemia with drug and interferon treatment. J Natl Cancer Inst 51:1367–1368, 1973.PubMedGoogle Scholar
  109. 109.
    Balkwill FR and Moodie EM: Positive interactions between human interferon and cyclophosphamide in a human tumor model system. Cancer Res 44:904–909, 1984.PubMedGoogle Scholar
  110. 110.
    Slater LM, Wetzel MW, and Cesario T: Combined interferon antimetabolite therapy of murine L1210 leukemia. Cancer 48:5–9, 1981.PubMedGoogle Scholar
  111. 111.
    Marquet RL, Schellekens J, Dijkema R, Westbroek DL, and Jeekel J: Effects of interferon and chemotherapy on tumour growth in rats. In: The Biology of the Interferon System 1983, E DeMaeyer and H Scheleekens (eds). Amsterdam: Elsevier Science Publishers, p 431–436, 1983.Google Scholar
  112. 112.
    Marquet RL, Schellekens H, Westbroek DL, and Jeekel J: Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats Int J Cancer 31:223–226, 1983.PubMedGoogle Scholar
  113. 113.
    Groveman DS, Borden EC, Merritt JA, Robins HI, Steeves R, and Bryan GT: Augmented antiproliferative effects of interferons at elevated temperatures against human bladder carcinoma cell lines. Cancer Res 44:5517–5522, 1984.PubMedGoogle Scholar
  114. 114.
    Fleischmann WR Jr, Fleischmann CM, and Gindhart TD: Effect of hyperthermia on the antiproliferative activities of murine alpha-, beta- and gamma-interferon: Differential enhancement of murine gamma-interferon: Cancer Res 46:8–13, 1986.PubMedGoogle Scholar
  115. 115.
    Aapro MS, Alberts DS, and Salmon SE: Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 10:161–166, 1983.PubMedGoogle Scholar
  116. 116.
    Renton KW and Mannering GJ: Depression of hepatic cytochrome P-450-dependent mono-oxygenase systems with administered interferon inducing agents. Biochem Biophys Res Comm 73:343–348 (1976).PubMedGoogle Scholar
  117. 117.
    Balkwill FR, Mowchowitz S, Seilman SS, Moodie EM, Griffin DB, Fantes KH, and Wolf CR: Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes. Cancer Res 44:5249–5255, 1984.PubMedGoogle Scholar
  118. 118.
    Gresser I, Maury C, and Brouty-Boye D: Mechanism of the antitumor effect of interferon in mice. Nature 239:167–168, 1972.PubMedGoogle Scholar
  119. 119.
    Blalock JE and Baron S: Interferon-induced transfer of viral resistance between animal cells. Nature 269:422–425, 1977.PubMedGoogle Scholar
  120. 120.
    Palladino MA, Svedersky LP, and Shepard HM: Interleukin regulation of the immune system TRIS’. In: ibid, p 139–147, 1984.Google Scholar
  121. 121.
    Fiers W, Devos R, Remaut E, Fransen L, Tavenier J, Marmenhout A, Guisez Y, and Van der Heyden J: Interferon gamma and its synergism with tumor necrosis factor in human and murine systems. In: The Interferon System, F Dianzani and GB Rossi (eds). New York: Raven Press, p 343–347.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1987

Authors and Affiliations

  • Paul P. Trotta
  • Robert J. Spiegel

There are no affiliations available

Personalised recommendations